Valuation
- Market cap
- 2,281,000
- Revenue TTM
- $820,000
- Net income TTM
- $-14,030,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -1,710.98%
- Debt to equity
- 0.00
Trading
- Volume
- 549,500
- Avg volume
- 3,665,506
- Day's range
- $0.40 – $0.46
- Shares out
- 5,241,000
- Stochastic %K
- 12%
- Beta
- 2.61
- Analysts
- Strong Buy
- Price target
- —
Company profile
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Im...
Show more
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 513 620 4101
- Website
- https://www.onconetix.com
- Address
- 201 East Fifth Street, Suite 1900, Cincinnati, United States
Latest news
No headlines yet.
